State Street
ORIC icon

State Street’s Oric Pharmaceuticals ORIC Stock Holding History

State Street’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53M Buy
4,894,000
+1,191,804
+32% +$10.8M ﹤0.01% 1808
2026
Q1 		$46.9M Sell
3,702,196
-556,201
-13% -$6.31M ﹤0.01% 1775
2025
Q4 		$34.8M Buy
4,258,397
+1,854,458
+77% +$21.3M ﹤0.01% 1953
2025
Q3 		$28.8M Buy
2,403,939
+771,823
+47% +$8.12M ﹤0.01% 2042
2025
Q2 		$16.6M Sell
1,632,116
-564,433
-26% -$3.79M ﹤0.01% 2291
2025
Q1 		$12.3M Buy
2,196,549
+350,287
+19% +$3.06M ﹤0.01% 2399
2024
Q4 		$14.9M Sell
1,846,262
-91,907
-5% -$843K ﹤0.01% 2392
2024
Q3 		$19.9M Sell
1,938,169
-318,059
-14% -$3.14M ﹤0.01% 2207
2024
Q2 		$16M Buy
2,256,228
+540,147
+31% +$4.84M ﹤0.01% 2285
2024
Q1 		$23.6M Buy
1,716,081
+923,007
+116% +$11M ﹤0.01% 2121
2023
Q4 		$7.3M Buy
793,074
+74,060
+10% +$536K ﹤0.01% 2751
2023
Q3 		$4.35M Sell
719,014
-14,598
-2% -$120K ﹤0.01% 2985
2023
Q2 		$5.69M Buy
733,612
+623,532
+566% +$3.54M ﹤0.01% 2934
2023
Q1 		$627K Hold
110,080
– – ﹤0.01% 3669
2022
Q4 		$648K Hold
110,080
– – ﹤0.01% 3674
2022
Q3 		$352K Hold
110,080
– – ﹤0.01% 3907
2022
Q2 		$493K Sell
110,080
-483,469
-81% -$1.93M ﹤0.01% 3829
2022
Q1 		$3.17M Sell
593,549
-678,279
-53% -$6.11M ﹤0.01% 3389
2021
Q4 		$18.7M Buy
1,271,828
+211,929
+20% +$3.3M ﹤0.01% 2521
2021
Q3 		$22.2M Sell
1,059,899
-192,014
-15% -$3.89M ﹤0.01% 2406
2021
Q2 		$22.1M Sell
1,251,913
-113,652
-8% -$2.49M ﹤0.01% 2444
2021
Q1 		$33.5M Buy
1,365,565
+1,006,522
+280% +$31.8M ﹤0.01% 2027
2020
Q4 		$12.2M Buy
359,043
+238,723
+198% +$6.85M ﹤0.01% 2516
2020
Q3 		$3.01M Buy
120,320
+22,329
+23% +$531K ﹤0.01% 3033
2020
Q2 		$3.31M Buy
+97,991
New +$3.13M ﹤0.01% 2971

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIHC Capital Management Central $104M AUM

State Street's ORIC Position: Q2 2026 in Review

State Street increased its Oric Pharmaceuticals (ORIC) stake by 32% in Q2 2026, buying an estimated $10.8M and bringing the position to 4,894,000 shares worth $53M. The position accounts for ﹤0.01% of the portfolio, ranked #1808.

State Street first reported a position in ORIC in Q2 2020 and has held it in 25 quarters since. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • State Street held 4,894,000 shares of Oric Pharmaceuticals worth $53M as of Q2 2026.
  • State Street bought 1,191,804 Oric Pharmaceuticals shares in Q2 2026, an estimated $10.8M.
  • Oric Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q2 2026, its #1808 holding.
  • State Street first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • 181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.